UNDERWRITING AGREEMENT BG MEDICINE, INC. [# of firm shares] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 1st, 2011 • BG Medicine, Inc. • Services-medical laboratories • New York
BG Medicine, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”) an aggregate of [# of firm shares] shares of common stock, par value $ 0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [# of shoe shares] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. As used herein, the “Representatives” shall mean Lazard Capital Markets LLC (“LCM”).
CONFIDENTIAL GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENTGalectin-3 License and Distribution Agreement • February 1st, 2011 • BG Medicine, Inc. • Services-medical laboratories • Delaware
This GALECTIN -3 LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”), entered into as of December 14, 2010 (the “Effective Date”), by and between Siemens Healthcare Diagnostics Inc, a corporation of the state of California, having its principal place of business at 511 Benedict Avenue, Tarrytown, NY 10591 (“SIEMENS”) and BG Medicine, Inc., a corporation of the state of Delaware, having its principal place of business at 610N Lincoln Street, Waltham, MA 02451 (“BGM”).
